Denmark-based biotech Curasight making strides in cancer therapies

October 10, 2016 Christoph Graener

CSO and Co-Founder of Curasight Andreas Kjaer spoke with Informa Pharma Intelligence at BioPharm America about his company’s efforts to develop novel, innovative radionuclide therapies for cancer. With two completed Phase I trials and an ongoing Phase II study with its lead candidate in breast cancer, this Denmark-headquartered biotech also is developing companion diagnostic PET imaging ligands to improve diagnosis, treatment and outcomes in cancer. Krasilnikoff also talked about Curasight’s efforts to raise its profile in North America, including potential partnering talks at BioPharm America in Boston.

Interviewer: Joe Haas – Senior Writer, Scrip
Interviewee: Andreas Kjaer – CSO and Co-Founder, Curasight

Previous Article
A glimpse into Pharma’s partnering world
A glimpse into Pharma’s partnering world

Guest post by Doro Shin, Thought Leadership Manager at Informa Pharma Intelligence   Fortune Magazine once ...

Next Article
Kura Oncology develops drug therapy for HRAS mutation cancers
Kura Oncology develops drug therapy for HRAS mutation cancers

Kura Oncology CEO Troy Wilson spoke about his company's precision medicine approach to treating cancer. Its...